Volagidemab is under clinical development by Remd Biotherapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Volagidemab’s likelihood of approval (LoA) and phase transition for Type 1 Diabetes (Juvenile Diabetes) took place on 25 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Volagidemab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Volagidemab (REMD-477, AMG-477) is under development for treatment of type 2 diabetes, type 1 diabetes, myocardial infarction, systolic heart failure and other indications. It is administered through subcutaneous route. The drug candidate is a fully human antibody that binds and blocks signaling via the human glucagon receptor (GCGR). It was also under development for the treatment of obesity.
Remd Biotherapeutics overview
Remd Biotherapeutics is a biopharmaceutical company. The company focus on discovering and developing bio-medicines to treat diabetes, cancer, and other diseases. Its pipeline products include REMD 477 and others. Remd Biotherapeutics offers REMD 477 for the treatment of type 1 and type 2 diabetes, and for cardiovascular and other indications. The company also develops products for immune-oncology, and cardiovascular and metabolism; and provides research and development services. Remd Biotherapeutics is headquartered in Camarillo, California, the US.
Quick View Volagidemab LOA Data
|Highest Development Stage|